LIVN (LivaNova) Additional Paid-In Capital : $2,205 Mil(As of Jun. 2024)

View and export this data going back to 1993. Start your Free Trial

What is LivaNova Additional Paid-In Capital?

LivaNova's quarterly additional paid-in capital increased from Dec. 2023 ($2,190 Mil) to Mar. 2024 ($2,193 Mil) and increased from Mar. 2024 ($2,193 Mil) to Jun. 2024 ($2,205 Mil).

LivaNova's annual additional paid-in capital increased from Dec. 2021 ($2,118 Mil) to Dec. 2022 ($2,158 Mil) and increased from Dec. 2022 ($2,158 Mil) to Dec. 2023 ($2,190 Mil).

LivaNova Additional Paid-In Capital Historical Data

The historical data trend for LivaNova's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LivaNova Additional Paid-In Capital Chart

LivaNova Annual Data

Trend

Apr14

Apr15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

1,734.87

1,768.16

2,117.96

2,157.72

2,189.52

LivaNova Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Additional Paid-In Capital	Get a 7-Day Free Trial															2,169.35	2,180.66	2,189.52	2,192.68	2,204.58

LivaNova Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

LivaNova Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of LivaNova's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

LivaNova Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » LivaNova PLC (NAS:LIVN) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

LIA:Germany LIA:Germany

Address

20 Eastbourne Terrace, London, GBR, W2 6LG

Website

https://www.livanova.com

UK-based LivaNova was born of a combination between Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management and heart valve businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.

Executives

Francesco Bianchi	director	C/O LIVANOVA PLC, 5 MERCHANT SQUARE, LONDON X0 W2 1AY
Daniel Jeffrey Moore	director	100 CYBERONICS BVLD, HOUSTON TX 77058
James Christopher Barry	director	7475 LUSK BLVD, SAN DIEGO CA 92121
Damien Mcdonald	officer: COO	5 MERCHANT SQUARE, NORTH WHARF ROAD, LONDON X0 W21AY
Michael Damon Hutchinson	officer: Chief Legal Officer	2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Brooke Story	director	C/O SIGILON THERAPEUTICS, INC., 100 BINNEY STREET, SUITE 600, CAMBRIDGE MA 02142
Peter M Wilver	director
Alfred J Novak	director	325 NE 6TH ST, BOCA RATON FL 33432
William A Kozy	director	C/O BECTON DICKERSON & CO, 1 BECTON DR, FRANKLIN LAKES NJ 07417
Marco Dolci	officer: SVP Global Operations, R&D	VIA BENIGNO CRESPI 17, MILAN L6 20159
Todd C Schermerhorn	director	C/O C.R BARD INC, 730 CENTRAL AVE, MURRAY HILL NJ 07974
Alex Shvartsburg	officer: Interim CFO	20 EASTBOURNE TERRACE, LONDON X0 W26LG
Roy Khoury	officer: President, International	5 MERCHANT SQUARE, NORTH WHARF ROAD, LONDON X0 W21AY
Thad Allen Huston	officer: Chief Financial Officer	941 BLOOMFIELD ST, HOBOKEN NJ 07030
Seng Stacy Enxing	director	C/O HILL-ROM HOLDINGS, INC., SUITE 4100 180 NORTH STETSON AVENUE, CHICAGO IL 60601